208 related articles for article (PubMed ID: 34725462)
1. BPIFB1 inhibits vasculogenic mimicry via downregulation of GLUT1-mediated H3K27 acetylation in nasopharyngeal carcinoma.
Jiang X; Deng X; Wang J; Mo Y; Shi L; Wei F; Zhang S; Gong Z; He Y; Xiong F; Wang Y; Guo C; Xiang B; Zhou M; Liao Q; Li X; Li Y; Li G; Xiong W; Zeng Z
Oncogene; 2022 Jan; 41(2):233-245. PubMed ID: 34725462
[TBL] [Abstract][Full Text] [Related]
2. BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM.
Wei F; Wu Y; Tang L; He Y; Shi L; Xiong F; Gong Z; Guo C; Li X; Liao Q; Zhang W; Zhou M; Xiang B; Li X; Li Y; Li G; Xiong W; Zeng Z
Br J Cancer; 2018 Jan; 118(2):233-247. PubMed ID: 29123267
[TBL] [Abstract][Full Text] [Related]
3. BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression.
Wei F; Tang L; He Y; Wu Y; Shi L; Xiong F; Gong Z; Guo C; Li X; Liao Q; Zhang W; Ni Q; Luo J; Li X; Li Y; Peng C; Chen X; Li G; Xiong W; Zeng Z
Cell Death Dis; 2018 Apr; 9(4):432. PubMed ID: 29568064
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of BPIFB1 promotes apoptosis and inhibits proliferation via the MEK/ERK signal pathway in nasopharyngeal carcinoma.
Xu Y; Tao Z; Jiang Y; Liu T; Xiang Y
Int J Clin Exp Pathol; 2019; 12(1):356-364. PubMed ID: 31933752
[TBL] [Abstract][Full Text] [Related]
5. EBV‑LMP1 is involved in vasculogenic mimicry formation via VEGFA/VEGFR1 signaling in nasopharyngeal carcinoma.
Xu S; Bai J; Zhuan Z; Li B; Zhang Z; Wu X; Luo X; Yang L
Oncol Rep; 2018 Jul; 40(1):377-384. PubMed ID: 29749553
[TBL] [Abstract][Full Text] [Related]
6. BPIFB1, Serving as a Downstream Effector of EBV-miR-BART4, Blocks Immune Escape of Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.
Cai J; Xiao L; Liu J; Wang D; Zhou Y; Liao Z; Chen G
Biochem Genet; 2024 Mar; ():. PubMed ID: 38467887
[TBL] [Abstract][Full Text] [Related]
7. LPLUNC1 reduces glycolysis in nasopharyngeal carcinoma cells through the PHB1-p53/c-Myc axis.
Oyang L; Ouyang L; Yang L; Lin J; Xia L; Tan S; Wu N; Han Y; Yang Y; Li J; Chen X; Tang Y; Su M; Luo X; Li J; Xiong W; Zeng Z; Liao Q; Zhou Y
Cancer Sci; 2023 Mar; 114(3):870-884. PubMed ID: 36382614
[TBL] [Abstract][Full Text] [Related]
8. The potent tumor suppressor miR-497 inhibits cancer phenotypes in nasopharyngeal carcinoma by targeting ANLN and HSPA4L.
Wang S; Mo Y; Midorikawa K; Zhang Z; Huang G; Ma N; Zhao W; Hiraku Y; Oikawa S; Murata M
Oncotarget; 2015 Nov; 6(34):35893-907. PubMed ID: 26486082
[TBL] [Abstract][Full Text] [Related]
9. LPLUNC1 inhibits nasopharyngeal carcinoma cell growth via down-regulation of the MAP kinase and cyclin D1/E2F pathways.
Yang Y; Liao Q; Wei F; Li X; Zhang W; Fan S; Shi L; Li X; Gong Z; Ma J; Zhou M; Xiang J; Peng S; Xiang B; Deng H; Yang Y; Li Y; Xiong W; Zeng Z; Li G
PLoS One; 2013; 8(5):e62869. PubMed ID: 23650533
[TBL] [Abstract][Full Text] [Related]
10. Foxq1 promotes metastasis of nasopharyngeal carcinoma by inducing vasculogenic mimicry via the EGFR signaling pathway.
Luo Y; Wang J; Wang F; Liu X; Lu J; Yu X; Ma X; Peng X; Li X
Cell Death Dis; 2021 Apr; 12(5):411. PubMed ID: 33875643
[TBL] [Abstract][Full Text] [Related]
11. LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation.
Liao Q; Zeng Z; Guo X; Li X; Wei F; Zhang W; Li X; Chen P; Liang F; Xiang B; Ma J; Wu M; Tang H; Deng M; Zeng X; Tang K; Xiong W; Li G
Oncogene; 2014 Apr; 33(16):2098-109. PubMed ID: 23708661
[TBL] [Abstract][Full Text] [Related]
12. FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma.
Shu XS; Li L; Ji M; Cheng Y; Ying J; Fan Y; Zhong L; Liu X; Tsao SW; Chan AT; Tao Q
Carcinogenesis; 2013 Sep; 34(9):1984-93. PubMed ID: 23677067
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 reprograms the TGF-β-stimulated transcriptional program from a metastasis promoter to a tumor suppressor in nasopharyngeal carcinoma.
Li J; Wang W; Chen S; Cai J; Ban Y; Peng Q; Zhou Y; Zeng Z; Li X; Xiong W; Li G; Yi M; Xiang B
Cancer Lett; 2019 Feb; 442():1-14. PubMed ID: 30392786
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
[TBL] [Abstract][Full Text] [Related]
15. DLC-1, a candidate tumor suppressor gene, inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells.
Feng X; Li C; Liu W; Chen H; Zhou W; Wang L; Zhu B; Yao K; Jiang X; Ren C
Int J Oncol; 2013 Jun; 42(6):1973-84. PubMed ID: 23588806
[TBL] [Abstract][Full Text] [Related]
16. LPLUNC1 stabilises PHB1 by counteracting TRIM21-mediated ubiquitination to inhibit NF-κB activity in nasopharyngeal carcinoma.
Wang H; Zhou Y; Oyang L; Han Y; Xia L; Lin J; Tang Y; Su M; Tan S; Tian Y; Chen X; Luo X; Liang J; Rao S; Wang Y; Xiong W; Zeng Z; Wang H; Li G; Liao Q
Oncogene; 2019 Jun; 38(25):5062-5075. PubMed ID: 30886235
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of KLHDC4 Predicts a Poor Prognosis in Human Nasopharyngeal Carcinoma.
Lian YF; Yuan J; Cui Q; Feng QS; Xu M; Bei JX; Zeng YX; Feng L
PLoS One; 2016; 11(3):e0152820. PubMed ID: 27030985
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-203a-3p affects the biological characteristics of nasopharyngeal carcinoma by targeting vascular endothelial growth factor-C.
Hang W; Guo HM; Wu QL; Yan H; Liu G; Gao M
J Physiol Pharmacol; 2021 Aug; 72(4):. PubMed ID: 35072651
[TBL] [Abstract][Full Text] [Related]
19. HOPX hypermethylation promotes metastasis via activating SNAIL transcription in nasopharyngeal carcinoma.
Ren X; Yang X; Cheng B; Chen X; Zhang T; He Q; Li B; Li Y; Tang X; Wen X; Zhong Q; Kang T; Zeng M; Liu N; Ma J
Nat Commun; 2017 Feb; 8():14053. PubMed ID: 28146149
[TBL] [Abstract][Full Text] [Related]
20. DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway.
Ding S; Gao Y; Lv D; Tao Y; Liu S; Chen C; Huang Z; Zheng S; Hu Y; Chow LK; Wei Y; Feng P; Dai W; Wang X; Xia Y
EBioMedicine; 2022 Jul; 81():104100. PubMed ID: 35689852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
